Matrix metalloproteinases and coronary artery disease: A novel therapeutic target

Journal of Clinical Pharmacology

Volumn 37, Issue 11, 1997, Pages 991-1000

  Celentano, Diane C ^a,b   Frishman, William H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RESPONSE; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; ENZYME ANALYSIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MECHANICAL STRESS; PATHOGENESIS; REVIEW;

EID: 0030831896     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04278.x     Document Type: Review

References (63)

1. Mignatti P, Tsuboi R, Robbins E, Rifkin DB: In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor induced proteinases. J Cell Biol 1989; 108: 671-682.
2. Schnaper HW, Grant DS, Stotler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, Bird RE, Hoythya M, Fuerst TR, French DL, Quigley JP, Kleinman HK: Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993; 156:235-246.
3. Murphy AN, Unsworth EJ, Stetler-Stevenson: Tissue inhibitor of metalloproteinase-2 inhibits FGF-induced human microvasculature endothelial cell proliferation. J Cell Physiol 1993:157:351-358.
4. Van Wart HE, Birkedal-Hansen H: The cysteine switch: a principle of regulation of metallo-proteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990:87:5578-5582.
5. Birkedal-Hansen H, Moore VVG, Boddon MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Egler JA: Matrix metalloproteinase. A review. Crit Rev Oral Bio Med 1993;4:197-250.
6. G. Docherty AJP, Murphy G: The tissue metalloproteinase family and the inhibitor TIMP: a study using DNAs and recombinant proteins. Ann Rheum Dis 1990;49:469-479.
7. Matrisian LM: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 6:121-125.
8. Unemori EN, Hibbs MS, Amento EP: Constitutive expression of a 92-KD gelatinase by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines. J Clin Invest 1991; 88:1656-1662.
9. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P: Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75:181-189.
10. Nagase H, Enghild JJ, Suzuki K, Salvesen G: Stepwise activation mechanisms of the precursor of matrix metalloproteinase3 by proteinasos and murcuric acetate. Biochem 1990; 29:5783-5789.
11. Murphy G, Willenbrock F, Crabbe T, O'Shea M, Ward R, Atkinson S, O'Connoll J, Docherty A: Regulation of matrix metalloproteinase activity. Ann NY Acad Sci 1994:732:31-41.
12. Meyer BJ, Fernandez Ortiz A, Mailhac A, Falk E, Badimon L, Michael AD, Chesebro JH, Fustor V, Badimon JJ: Local delivery of r-hirudin by a double balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 1994; 90:2474-2480.
13. Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995:77:863-868.
14. Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi I, Salvesen G, Nagase H: Matrix metallo-proteinase-2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymatic properties. EUT J Biochem 1990;194:721-730.
15. Crabbe T, loannou C, Docherty AJP: Human progelatinase A can be activated by autolysis at a rate that is concentration dependent and enhanced by heparin bound to the C-terminal domain. EurJ Biochem 1993:218:431-438.
16. Murphy G, Willenbrock F, Ward RV, Cockett MI, Eaton D, Docherty AJP: The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J 1992;283:637-641.
17. Overall CM, Sodek J: Concanavalin A produces a matrix-degrative phenotype in human flbro-blasts. Induction and endogenous activation of collagenases, 72 Kd golatinases and PUMP-1 is accomplished by suppression of the tissue inhibitor of matrix metalloproteinases. /Biol Chem 1990:265:21141-21151.
18. Willenbrock FT, Crabbe TM, Slocombe PM, Sutton CW, Docherty JP, Cockett MI, O'Shea M, Brocklehurst K, Phillips IR, Murphy G: The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: A kinetic analysis of the inhibition of gelatinase A. Biochem 1993; 32:4330-4337.
19. Yang TT, Hawkes SP: Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci USA 1992; 89:10676-10680.
20. Lee E, Vaughan DE, Parikh SH, Grodzinsky AJ, Libby P, Lark MW, Lee RT: Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cul-lured human vascular smooth muscle cell. Circ Res 1996:78:44-49.
21. Malik N, Greenfield BW, Wahl AF, Kiener PA: Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996;156:3952-3960.
22. Lambert ÇA, Soudant EP, Nusgens BV, Lapiere CM: Pretranslational regulation of extra-cellular matrix macromolecules and collagenase expression in flbroblasts by mechanical forces. Lab Invest 1992; 66:444-451.
23. Ross R: The pathogenesis of atherosclerosis. A prospective for the 1990s. Nature 1993; 362:801.
24. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT: Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994; 75:41-54.
25. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM: Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73:209-215.
26. Sandy JD, Boynton RE, Flannery CR: Analysis of the catabolism of aggrecan in cartilage explants by quantitation of peptides from the three globulin domains. J Biol Chem 1991; 266:8198-8205.
27. Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA: The interglobulin domain of cartilage aggrecan is cleaved by PUMP, gelatinases and cathepsin B. J Biol Chem 1992; 267:19470-19474.
28. Chin JR, Murphy G, Werb Z; Stromelysin, a connective tissuedegrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenases. J Biol Chem 1992; 260:12367-12376.
29. Ogata Y, Enghild JJ, Nagase H: Matrix metalloproteinase-3 (stromolysin) activates the precursor for the human matrix metalloproteinase-9. J Biol Chem 1992; 267:3581-3584.
30. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild to moderate coronary artery disease? Circulation 1988; 78:1157-1166.
31. Fuster V, Falk E, Fallon JT, Badimon L, Chesobro JH, Badimon JJ: The three processes leading to post percutaneous transluminal coronary angiography restenosis: dependence on the lesion substrate. Thromb Haemost 1995; 74:552-559.
32. Hanet C, Wijns W, Michel X, Schroeder E: Influence of balloon size and stenosis morphology on immediate and delayed elastic recoil after percutaneous transluminal coronary angiolasty. J Am Coll Cardiol 1991; 18:506-511.
33. Hjemdhal-Monsen CE, Ambrose JA, Borneo S, Cohen M, Sherman W, Alexopoulos D, Gorlin R, Fuster V: Angiographic patterns of balloon inflation during percutaneous transluminal coronary angioplasty: Role of pressure-diameter curves in studying distensibility and elasticity of the stenotic lesion and the mechanism of dilation. J Am Coll Cardiol 1990; 16:569-575.
34. Fernandez Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L: Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23:1562-1569.
35. Clowes AW, Reidy MA, Clowes MM: Kinetics of cellular proliferation after arterial injury. I: smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49:327-333.
36. Jackson CL, Raines EW, Ross R, Reidy MA: Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterio Thromb 1993; 13:1218-1226.
37. Dendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA: Smooth muscle cell migration and matrix metalloproteinases expression after arterial injury in the rat. Ci'rc Res 1994; 75:539-545.
38. Ross R, Raines EW, Bowen-Pepe DR: The biology of plateletderived growth factor (review). Cell 1986;46:155.
39. Heldin CH, Westermark B: Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Reg 1990; 1:555-566.
40. Reidy MA, Bendeck MP: The development of arterial lesions: a process controlled by multiple factors. In, Goldhaver SZ (ed): Coronary Restenosis, From Genetics to Therapeutics. New York: Marcel Dekker Inc.; 1997:55-67.
41. Majesky MW, Reidy MA, Bowen-Pope DP, Hart CE, Wilcox JN, Schwartz SM: PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 1990; 111:2149-2158.
42. Ferns GAA, Raines EW, Sprugal KH, Motani AS, Reidy MA, Ross R: Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.Science 1991; 253:1129-1132.
43. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW: Platelet-derived growth factor promotes smooth muscle migration and intimai thickening in a rat model of balloon angioplasty. J Clin Invest 1992; 89:507-511.
44. Bendeck MP, Irvin C, Reidy MA: Inhibition of matrix metallo-proteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78:38-43.
45. Clowes AW, Clowes MM, Au YPT, Reidy MA, Belin D: Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990;67:61-67.
46. G. Verstraete M: Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-261.
47. Takada A, Takada Y: Inhibition by transexamic acid of the conversion of single-chain tissue plasminogen activator to its two chain form by plasmin: the presence on tissue plasminogen activator of a site to bind with lysine binding sites of plasmin. Thromb Res 1989;55:717-725.
48. Clowes AW, Clowes MM, Kirkman TR, Jackson CL, Au YPT, Kenagy R: Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery. Circ Res 1992:70:1128-1136.
49. Au YPT, Clowes AW: Effects of heparin on interstitial collagenase and tissue plasminogen activator expression (abst). J Cell Biol 1990;111:234.
50. Wang H, Moore S, Alavi MZ: Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP) in rabbit aortic neointima after selective de-endothelialization. Atherosclerosis 1996:126:95-104.
51. Hayakawa T, Yamashita K, Tunyawa K, Uchijima E, Iwata K: Growth promoting activity of tissue inhibitor of metalloprotoinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEES Lett 1992:298:29-32.
52. Richardson PD, Davies MJ, Born GVR: Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989:2:941-944.
53. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT: Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathologic correlation. Circulation 1993; 87:1179-1187.
54. Schrocder AP, Falk E: Pathophysiology and inflammatory aspects of plaque rupture. Cardiol Clinics 1996; 14:211-220.
55. Shah PK, Falk E, Badimon JJ, Fernandez Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Circulation 1995:95:1565-1569.
56. Galis ZS, Sukhova GK, Lark M\V, Libby P: Increased expression of matrix metalloprotineases and mtrix degrading activity in vulnerable regions of human atheroscleroticplaques. JCIin Invest 1994:94:2493-2503.
57. Brown DL, Hibbs MS, Kearney M, LoushnTCIsner JM: Identification of 92 KD gelatinase in human coronary atherosclerotic lesions, association of active enzyme synthesis with unstable angina. Circulation 1995; 91:2125-2131.
58. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc NatI Acad Sci USA 1995; 92:402-406.
59. Fernandez Ortiz A, Meyer BJ, Mailhac A, Falk E, Badimon L, Fallon JT, Fuster V, Chesebro JH, Badimon JJ: A new approach for local intravascular drug delivery: iontophoretic balloon. Circulation 1994:89:1518-1522.
60. GO. Arner EC, Pratta MA, Freimark B, Lischwe M, Trzakos JM, Magolda RL, Wright SW: Isothiazolones interfere with normal matrix metalloproteinase activation and inhibit cartilage proteoglycan dégradation. Biochem ] 1996; 318:417-424.
61. Van Wart HE, Schwartz MA: Synthetic inhibitors of bacterial and mammalian interstitial collagenases. Prog Med Chem 1992;29:271-334.
62. Chandrasekhar S, Harvey AK, Dell CP, Ambler SJ, Smith CW: Identification of a novel chemical series that blocks interleukin1-stimulated metalloproteinase activity in chondrocytes. J PharmacolExp 1995:273:1519-1528.
63. Zucker S, Conner C, DiMassirio BI, Ende H, Drews M, Seiki M, Bahou WF: Thrombin induces the activation of progelatinase A in vascular endothelial cells, physiologic regulation of angiogonesis. J Biol Chem 1995; 40:23730-23738.